medication

Apixaban

Also known as: Eliquis

Chemical structure of Apixaban (PubChem CID 10182969)
Structure via PubChem
Half-life
12 h
Typical timing
morning
Food rule
either
Default unit
mg

Overview

Apixaban, marketed under the brand name Eliquis, is an oral anticoagulant classified as a direct factor Xa inhibitor. It is used to prevent and treat various thromboembolic conditions, where blood clots obstruct blood vessels. Unlike older anticoagulants such as warfarin, apixaban does not require routine blood monitoring and has a more predictable anticoagulant effect. (FDA label, DrugBank) Apixaban works by selectively and reversibly inhibiting factor Xa, a key enzyme in the coagulation cascade. By blocking factor Xa, apixaban prevents the conversion of prothrombin to thrombin, thereby reducing thrombin generation and the formation of fibrin, which is essential for clot formation. This targeted action makes it effective in preventing and treating conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke in patients with nonvalvular atrial fibrillation (NVAF). (DrugBank, EMA SmPC) Apixaban is generally taken twice daily. Its rapid onset of action and relatively short half-life contribute to its therapeutic profile. The dosage is user-directed and must be set by a licensed clinician, as it depends on the specific condition being treated, patient renal function, and other individual factors. (FDA label)

Deep dive

Tap a section to expand.

Known interactions

  • Category rule: supplement × medication
    Note

    Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).

    Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist.

  • Category rule: vitamin × medication
    Note

    Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).

    Specific pairs are checked against a licensed source; confirm with your provider.

  • Compound-pair rule
    Caution

    Additive antiplatelet/antithrombotic effect increases bleeding risk.

    Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments.

  • Compound-pair rule
    Caution

    Additive antiplatelet/antithrombotic effect increases bleeding risk.

    Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments.

  • Compound-pair rule
    Caution

    Additive antiplatelet/antithrombotic effect increases bleeding risk.

    Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments.

  • Compound-pair rule
    Caution

    Additive antiplatelet/antithrombotic effect increases bleeding risk.

    Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments.

  • Compound-pair rule
    Caution

    Additive antiplatelet/antithrombotic effect increases bleeding risk.

    Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments.

  • Compound-pair rule
    Caution

    Additive antiplatelet/antithrombotic effect increases bleeding risk.

    Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments.

  • Compound-pair rule
    Caution

    Additive antiplatelet/antithrombotic effect increases bleeding risk.

    Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments.

  • Compound-pair rule
    Caution

    Additive antiplatelet/antithrombotic effect increases bleeding risk.

    Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments.

  • Compound-pair rule
    Caution

    Vitamin K reverses vitamin K antagonist activity and shifts INR.

    Keep vitamin K intake consistent; do not start or stop supplementation without INR monitoring.

  • Compound-pair rule
    Caution

    Vitamin K2 can shift INR on warfarin.

    Discuss with prescribing clinician before adding K2.

Frequently asked

Sources referenced

["U.S. Food and Drug Administration (FDA)", "European Medicines Agency (EMA)", "DrugBank Online", "National Institutes of Health (NIH) - PubMed, ClinicalTrials.gov", "Mayo Clinic", "Cochrane Library"]

Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.

Related compounds

Others in the medication category or studied for the same goals.

Track Apixaban in Stackwise

Add it to your stack. We'll schedule doses, check interactions against everything else you take, and remind you at the right time.

Sign up free →